Simple graphic method for estimation of prostate-specific antigen doubling time

Urology

Volumn 67, Issue 2, 2006, Pages 408-409

  Sengupta, Shomik ^a   Slezak, Jeffrey M ^a   Blute, Michael L ^a   Bergstralh, Eric J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN FUNCTION; CIRCADIAN RHYTHM; CONFERENCE PAPER; DISEASE COURSE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATITIS; REGRESSION ANALYSIS;

HUMANS; MALE; MATHEMATICS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 31944432720     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.09.007     Document Type: Conference Paper

References (10)

1. S. Sengupta, R.P. Myers, J. Slezak Pre-operative prostate-specific antigen doubling-time and velocity are strong and independent predictors of outcomes following radical prostatectomy J Urol 174 6 2005 2191 2196
2. S.G. Roberts, M.L. Blute, E.J. Bergstralh PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc 76 2001 576 581
3. G.E. Hanks, A.L. Hanlon, W.R. Lee Pretreatment prostate-specific antigen doubling times clinical utility of this predictor of prostate cancer behavior Int J Radiat Oncol Biol Phys 34 1996 549 553
4. A.V. D'Amico, M.H. Chen, K.A. Roehl Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
5. D.B. McLaren, M. McKenzie, G. Duncan Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma Cancer 82 1998 342 348
6. A.V. D'Amico, J.W. Moul, P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
7. S.J. Freedland, E.B. Humphreys, L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
8. H.P. Schmid, J.E. McNeal, T.A. Stamey Observations on the doubling time of prostate cancer the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume Cancer 71 1993 2031 2040
9. R.T. Vollmer, S. Egawa, S. Kuwao The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma a study of 94 Japanese men Cancer 94 2002 1692 1698
10. http://www.mskcc.org/mskcc/html/10088.cfm. Accessed August 5, 2005.